TRIAL WATCH PCSK9 antibody reduces LDL cholesterol

被引：30
|
作者：
Crunkhorn, Sarah
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 01期
关键词：
D O I：
10.1038/nrd3633
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [21] PCSK9 Inhibitors The Magic Bullet for LDL Cholesterol Reduction?
    Richter, Kurt
    Barthel, Andreas
    Bornstein, Stefan R.
    El-Armouche, Ali
    Wagner, Michael
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (12) : 863 - U181
  • [22] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [23] PCSK9 and LDL cholesterol: unravelling the target to design the bullet
    Costet, Philippe
    Krempf, Michel
    Cariou, Bertrand
    TRENDS IN BIOCHEMICAL SCIENCES, 2008, 33 (09) : 426 - 434
  • [24] Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1
    Shiori Sato
    Yumiko Akamine
    Hideaki Kagaya
    Mitsuru Saito
    Takamitsu Inoue
    Kazuyuki Numakura
    Tomonori Habuchi
    Shigeru Satoh
    Masatomo Miura
    Pharmacological Reports, 2020, 72 : 622 - 630
  • [25] Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1
    Sato, Shiori
    Akamine, Yumiko
    Kagaya, Hideaki
    Saito, Mitsuru
    Inoue, Takamitsu
    Numakura, Kazuyuki
    Habuchi, Tomonori
    Satoh, Shigeru
    Miura, Masatomo
    PHARMACOLOGICAL REPORTS, 2020, 72 (03) : 622 - 630
  • [26] PCSK9 MUTATIONS AND LDL-CHOLESTEROL IN THE BOGALUSA HEART STUDY
    Hallman, D. M.
    Srinivasan, S.
    Chen, W.
    Boerwinkle, E.
    Berenson, G.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [27] Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol
    Newman, Connie B.
    Tobert, Jonathan A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04): : 784 - 790
  • [28] Common inactivating mutations in PCSK9 cause low LDL cholesterol
    Brunham, LR
    CLINICAL GENETICS, 2005, 67 (06) : 476 - 477
  • [29] An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo
    Schiele, Felix
    Park, John
    Redemann, Norbert
    Luippold, Gerd
    Nar, Herbert
    JOURNAL OF MOLECULAR BIOLOGY, 2014, 426 (04) : 843 - 852
  • [30] PCSK9, a novel target for lowering LDL cholesterol: promise and progress
    Tavori, Hagai
    Fazio, Sergio
    Linton, MacRae F.
    CLINICAL LIPIDOLOGY, 2012, 7 (06) : 611 - 615
12345